Dr Erica R Drennen, MD | |
9403 Crown Crest Blvd Ste 200, Parker, CO 80138-8991 | |
(720) 721-1670 | |
(720) 721-8117 |
Full Name | Dr Erica R Drennen |
---|---|
Gender | Female |
Speciality | Obstetrics/gynecology |
Experience | 17 Years |
Location | 9403 Crown Crest Blvd Ste 200, Parker, Colorado |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1982804837 | NPI | - | NPPES |
33584281 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 50069 (Colorado) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Portercare Adventist Health System | 0941110886 | 547 |
News Archive
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.
Keryx Biopharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering of common stock consisting of 8,234,000 shares at $8.49 per share.
The pancreas is an important part of the digestive system that converts the food we eat into fuel for the body's cells. Responsible for two main functions, the pancreas helps digestion and regulates blood sugar. However, the pancreas can become inflamed, which causes pancreatitis to occur.
Researchers from Memorial Sloan Kettering Cancer Center are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.
› Verified 2 days ago
Entity Name | Portercare Adventist Health System |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1760761928 PECOS PAC ID: 0941110886 Enrollment ID: O20090115000327 |
News Archive
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.
Keryx Biopharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering of common stock consisting of 8,234,000 shares at $8.49 per share.
The pancreas is an important part of the digestive system that converts the food we eat into fuel for the body's cells. Responsible for two main functions, the pancreas helps digestion and regulates blood sugar. However, the pancreas can become inflamed, which causes pancreatitis to occur.
Researchers from Memorial Sloan Kettering Cancer Center are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.
› Verified 2 days ago
Entity Name | Questcare Obstetrics Colorado Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1417295932 PECOS PAC ID: 3072759133 Enrollment ID: O20130415000372 |
News Archive
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.
Keryx Biopharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering of common stock consisting of 8,234,000 shares at $8.49 per share.
The pancreas is an important part of the digestive system that converts the food we eat into fuel for the body's cells. Responsible for two main functions, the pancreas helps digestion and regulates blood sugar. However, the pancreas can become inflamed, which causes pancreatitis to occur.
Researchers from Memorial Sloan Kettering Cancer Center are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Erica R Drennen, MD 9403 Crown Crest Blvd Ste 200, Parker, CO 80138-8991 Ph: (720) 721-1670 | Dr Erica R Drennen, MD 9403 Crown Crest Blvd Ste 200, Parker, CO 80138-8991 Ph: (720) 721-1670 |
News Archive
The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.
Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.
Keryx Biopharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering of common stock consisting of 8,234,000 shares at $8.49 per share.
The pancreas is an important part of the digestive system that converts the food we eat into fuel for the body's cells. Responsible for two main functions, the pancreas helps digestion and regulates blood sugar. However, the pancreas can become inflamed, which causes pancreatitis to occur.
Researchers from Memorial Sloan Kettering Cancer Center are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.
› Verified 2 days ago
Dr. Candice Jessica Geist, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9403 Crown Crest Blvd Ste 200pinn, Parker, CO 80138 Phone: 303-840-8780 Fax: 303-840-8795 | |
Heidi A Gage, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9395 Crown Crest Blvd, Parker, CO 80138 Phone: 303-269-4000 Fax: 303-306-7753 | |
Susanna Choi, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 10233 S Parker Rd, Unit 200, Parker, CO 80134 Phone: 303-805-1264 Fax: 303-805-1164 | |
Sunmee Lee, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9397 Crown Crest Blvd, Suite 220, Parker, CO 80138 Phone: 303-721-1670 Fax: 303-721-8117 | |
Ms. Lorie C Jones, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 9397 Crown Crest Blvd, 431, Parker, CO 80138 Phone: 720-851-8230 Fax: 720-851-8970 | |
Diane M Schmitz, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 9397 Crown Crest Blvd, Suite 320, Parker, CO 80138 Phone: 303-766-0197 Fax: 303-766-0187 | |
Dr. Oscar Antonio Aguirre, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 11953 Lioness Way, Suite 101, Parker, CO 80134 Phone: 303-322-0500 Fax: 303-322-0772 |